Where are the global breakthroughs, opportunities and developments in cancer research?

This is the latest episode of the free DDW narrated podcast, titled "Where are the global breakthroughs, opportunities and developments in cancer research?", which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: "Global breakthroughs in cancer drug discovery", "The Achilles' heel of cancer", and "Immunotherapy is here to stay". At the time of writing in the first article, AstraZeneca UK had appointed David Brocklehurst as Head of Oncology in the UK. I spoke with him about how AstraZeneca is innovating to displace chemotherapy and research areas of significance. In the second article, Genoscience Pharma's Philippe Halfon and Eric Raymond share their expertise on targeting the recycling of unsustainable production of palmitoylated cancer-associated proteins.  In the third article, I spoke with Frédéric Triebel, the French immunologist/oncologist who is best known for his 1990 discovery of the LAG-3 immune control mechanism. Triebel shares insights from his career, expands on his experience with the company he founded, Immutep, and comments on the future of immuno-oncology.